Ingevity (NGVT) shares came into focus after the company booked a long lived assets impairment charge of US$109.3 million in the fourth quarter and paired that with fresh 2026 net sales guidance.
See our latest analysis for Ingevity.
The impairment charge and weaker quarterly results appear to have cooled short term sentiment, with a 7 day share price return of 7.76% decline and a 30 day share price return of 9.09% decline. However, the 90 day share price return of 17.89% and 1 year total shareholder return of 50.15% point to momentum that has built over a longer stretch despite a weaker 3 year and 5 year total shareholder return.
If this kind of earnings driven move has your attention, it could be a good moment to look at 20 top founder-led companies as another way to spot companies shaping their own story.
With Ingevity shares sitting at US$66.08, a 20% discount to the average analyst price target of US$79.25 and an indicated 52% intrinsic discount, the question is whether there is still a buying opportunity here or if the market is already pricing in future growth.
Most Popular Narrative: 6.6% Undervalued
At a last close of $66.08 against a most-followed fair value of $70.75, the current price sits slightly below what this narrative suggests, putting the focus firmly on whether the long term cash flow story holds up.
Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.
Curious what kind of revenue mix and margin profile need to line up for that fair value to make sense? The core of this narrative leans on earnings returning from current losses, profitability stepping up meaningfully, and a future P/E that sits well below many peers. The specific mix of growth, profitability, and discount rate assumptions is what really drives that $70.75 figure.
Result: Fair Value of $70.75 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on APT margin pressure and tariff-related demand weakness not lasting long enough to undermine the assumed profit recovery and future P/E multiple.
Find out about the key risks to this Ingevity narrative.
Another View: Multiples Paint A Tougher Picture
The cash flow narrative suggests upside, but the current P/S ratio of 2x is higher than both the US Chemicals industry average of 1.1x and the peer average of 1.1x, and above a fair ratio of 1.6x. That kind of premium can shrink quickly if expectations change. How comfortable are you with that gap?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mix of optimism and concern in this story feels familiar, now is a good time to look through the data yourself, weigh the trade offs, and see how our take on 2 key rewards and 1 important warning sign lines up with your own view.
Looking for more investment ideas?
If this story has you thinking harder about where to put fresh capital, do not stop here. The broader market is full of other opportunities to compare.
- Spot potential value setups by scanning our list of 46 high quality undervalued stocks, so you are not relying on a single stock to carry your thesis.
- Strengthen your focus on resilience by checking the solid balance sheet and fundamentals stocks screener (41 results), where debt levels and financial footing sit at the center of the screen.
- Hunt for lesser known opportunities using the screener containing 23 high quality undiscovered gems and see which names might be next on investors radar before interest builds.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com